

**NORTHEAST LOUISIANA SICKLE CELL ANEMIA
RESOURCE FOUNDATION, INCORPORATED
MONROE, LOUISIANA**

**FINANCIAL STATEMENTS
AND INDEPENDENT AUDITOR'S REPORT
WITH SUPPLEMENTAL INFORMATION
For The Year Ended December 31, 2001**

**NORTHEAST LOUISIANA SICKLE CELL ANEMIA
 TECHNICAL RESOURCE FOUNDATION, INCORPORATED
 Monroe, Louisiana
 Financial Statements
 and Independent Auditor's Report
 As of and For the Year Ended December 31, 2001**

CONTENTS

	<u>STATEMENTS</u>	<u>PAGE NO.</u>
Independent Auditor's Report Statement and Supplemental Information		1-2
Financial Statements		
Statement of Financial Position	A	4
Statement of Activities	B	5
Statement of Cash Flows	C	6
Statement of Functional Expenses	D	7
Notes to the Financial Statements		8-12
Independent Auditor' Report and Compliance and Internal Control Structure Based on an Audit Of Basic Financial Statements Performed In Accordance with Government Auditing Standards		
Supplemental Information: Schedules		
Schedule of Financial Position		16
Schedule of Activities		17
Schedule of Cash Flow		18
Schedule of Functional Expenses		19



ROSIE D. HARPER

Certified Public Accountant

141 DeSiard Street, Suite 325
Monroe, Louisiana 71201

Office 318-387-8008

FAX 318-387-0806

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of
Northeast Louisiana Sickle Cell Anemia
Technical Resource Foundation, Incorporated
Monroe, Louisiana

I have audited the accompanying statement of financial position of Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Incorporated (a nonprofit organization) as of December 31, 2001, and the related statements of activities, cash flows and functional expenses for the year then ended. These financial statements are the responsibility of the Organization's management. My responsibility is to express an opinion on these financial statements based on my audit.


I conducted my audit in accordance with generally accepted auditing standards and the standards applicable to the financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States. Those standards require that I plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. I believe that my audit provides a reasonable basis for my opinion.

In my opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Incorporated as of December 31, 2001, and the changes in its net assets and its cash flows for the year then ended in conformity with generally accepted accounting principles.

My audit was conducted for the purpose of forming an opinion on the financial statements taken as a whole. The supplemental information and schedules are presented for purposes of additional analysis and are not a required part of the basic financial statements. Such information has been subjected to the auditing procedures applied in the audit of the basic financial statements, and, in

INDEPENDENT AUDITOR'S REPORT

my opinion, is fairly stated in all material respects in relation to the basic financial statements taken as a whole.

A handwritten signature in cursive script that reads "Rosie D. Harper".

Rosie D. Harper
Certified Public Accountant

Monroe, Louisiana
February 28, 2002

FINANCIAL STATEMENTS

NORTHEAST LOUISIANA SICKLE CELL ANEMIA
 TECHNICAL RESOURCE FOUNDATION, INCORPORATED
 Statement of Financial Position
 December 31, 2001

Assets

Current Assets:

Cash and Cash Equivalents	\$ 120,289
Accounts Receivable	-
Total Current Assets	<u>120,289</u>

Physical Properties

Furniture and Equipment	26,161
Building	201,730
Accumulated Depreciation	(44,848)
Land	<u>1,000</u>
Total Physical Properties	<u>184,043</u>

Total Assets	<u><u>304,332</u></u>
--------------	-----------------------

Liabilities and Net Assets

Current Liabilities:

Accrued Liabilities	3,185
Deferred Revenue	<u>7,358</u>
Total Current Liabilities	<u>10,543</u>

Total Liabilities	<u>10,543</u>
-------------------	---------------

Net Assets:

Unrestricted, including \$184,043 invested in Physical Properties	<u>293,789</u>
Total Net Assets	<u>293,789</u>

Total Liabilities and Net Assets	<u><u>\$ 304,332</u></u>
----------------------------------	--------------------------

See accompanying notes to financial statements.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED

Statement of Activities

For the Year Ended December 31, 2001

Unrestricted Public Support and Revenues

Contributions	\$ 12,590
Donations	20,183
Investment Income	1,019
Total Unrestricted Public Support and Revenues	<u>33,792</u>

Reclassified Net Assets

Restrictions satisfied by payments	<u>73,993</u>
Total Reclassified Net Assets	<u>73,993</u>

Total Unrestricted Public Support, Revenues, and Reclassified Net Assets	<u>107,785</u>
--	----------------

Expenses

Program Expenses	26,514
General & Administrative Expenses	84,268
Total Expenses	<u>110,782</u>

Change in Unrestricted Net Assets	<u>(2,997)</u>
-----------------------------------	----------------

Temporarily Restricted Public Support and Revenues

Grants	74,509
Net Assets released from restrictions:	
Restrictions satisfied by payments	<u>(73,993)</u>

Total Temporarily Restricted Public Support, Revenues, and Net Assets Released From Restrictions	<u>516</u>
--	------------

Change in Temporarily Restricted Net Assets	<u>516</u>
---	------------

Total Change in Net Assets	<u>(2,481)</u>
-----------------------------------	----------------

Net Assets at the Beginning of Year	<u>296,270</u>
-------------------------------------	----------------

Net Assets at the End of Year	<u><u>\$ 293,789</u></u>
-------------------------------	--------------------------

See accompanying notes to financial statements.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA
 TECHNICAL RESOURCE FOUNDATION, INCORPORATED
 Statement of Cash Flows
 For the Year Ended December 31, 2001

Operating Activities		
Change in Net Assets		\$ (2,481)
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Provision for Depreciation		8,676
Decrease (Increase) in Grants Receivable		1,786
Increase (Decrease) in Accrued Liabilities		3,185
Increase (Decrease) in Deferred Income		4,894
Total Adjustments		<u>18,541</u>
Net Cash Provided by Operating Activities		<u>16,060</u>
 Investing Activities		
Acquisitions of Physical Properties		<u>(2,385)</u>
Net Cash Used by Investing Activities		<u>(2,385)</u>
 Increase (Decrease) in Cash and Cash Equivalents		13,675
 Cash and Cash Equivalents at the Beginning of Year		<u>106,614</u>
 Cash and Cash Equivalents at the End of Year		<u><u>120,289</u></u>
 Supplemental Information:		
Cash Equivalents		
Certificates of Deposits		<u><u>\$ 23,832</u></u>

See accompanying notes to financial statements.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA
 TECHNICAL RESOURCE FOUNDATION, INCORPORATED
 Statement of Functional Expenses
 For the Year Ended December 31, 2001

	General and Administrative	Program	Total
Personnel Costs			
Salaries and Wages	\$ 33,632	\$20,760	\$ 54,392
Payroll Taxes and other Fringe Benefits	2,573	1,588	4,161
Total Personnel Costs	<u>36,205</u>	<u>22,348</u>	<u>58,553</u>
Other Expenses			
Bank Charges	291	-	291
Bldg & Lawn Service	1,260	-	1,260
Car Allowance	700	-	700
Conferences, Conventions, & Meetings	271	-	271
Contributions	-	500	500
Depreciation	8,676	-	8,676
Fundraiser	462	-	462
Insurance	2,961	-	2,961
Internet	262	-	262
Miscellaneous	5,264	-	5,264
Occupancy	401	-	401
Postage and Delivery	557	-	557
Printing and Publication	463	-	463
Professional/Contractual	11,190	-	11,190
Repairs	802	-	802
Specific Assistance to Individuals	-	2,725	2,725
Supplies	4,000	-	4,000
Telephone	4,119	-	4,119
Travel	1,185	941	2,126
Utilities	5,199	-	5,199
Total Other Expenses	<u>48,063</u>	<u>4,166</u>	<u>52,229</u>
Total Functional Expenses	<u>\$ 84,268</u>	<u>\$26,514</u>	<u>\$ 110,782</u>

See accompanying notes to financial statements.

**Northeast Louisiana Sickle Cell Anemia Technical Resource
Foundation, Incorporated
Monroe, Louisiana**

**Notes to the Financial Statements
As of and for the Year Ended December 31, 2001**

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations

The Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Incorporated is a private non-profit organization domiciled in the State of Louisiana at Monroe, Louisiana. The Foundation is recognized as a tax-exempt (non-profit) organization under section 501 (c) (3) of the Internal Revenue Service Code. The Foundation is supported primarily through state and private grants, contributions and donations from members, and fund-raisers. The objectives of the Foundation are primarily to provide services to persons born with sickle cell anemia, a hereditary disorder. Such services include educational program, patient assistance programs, genetic counseling, research and social services. A Board of Directors consisting of twenty-eight (28) members governs the Foundation. The Board Members receive no compensation.

Basis of Presentation

The Foundation follows standards of accounting and financial reporting for voluntary health and welfare organizations as described in the American Institute of Certified Public Accountants' "Industry Guide for Audits of Voluntary Health and Welfare Organization." Accordingly, the financial statements are presented on an accrual basis of accounting.

Public Support and Revenue

In order to comply with restrictions, which donors place on grants and other gifts as well as designations made by its governing board, the principles of reporting net assets are used. Revenue and public support consists mainly of state and private grants, fundraising, and contributions. Grants and other contributions of cash and other assets are reported as permanently restricted if they are received with donor restrictions or restrictions designated by the governing board. Contributions are considered to be unrestricted unless restricted by the donor. All assets over which the Board of Directors has discretionary control have been included in the General Fund.

Fair Value of Financial Instruments

The carrying amounts of cash, cash equivalents, investments, and notes payable are reported in the statement of financial position at approximate fair values because of the short maturity of those instruments.

Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires the use of management's estimates. There were no estimates made during the audit period.

Depreciation

The Association follows the practice of capitalizing, at cost, all expenditures for fixed assets in excess of \$500. Depreciation is computed on a straight-line basis over the useful lives of the assets generally as follows:

Building and improvements	30 years
Furniture and equipment	7 years
Computers and accessories	5 years

The net fixed asset balance is reflected in the financial statements as a separate component in the net assets.

Cash and Cash Equivalents

The Foundation considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents for purposes of the statement of cash flows exclude permanently restricted cash and cash equivalents. Under state law, the agency may deposit funds in demand accounts, interest bearing accounts, money market accounts, or time deposits with state banks organized under Louisiana law and national banks having their principal offices in Louisiana. On December 31, 2001, Northeast Louisiana Sickle Cell Anemia Technical Resource Foundation, Incorporated had cash and cash equivalents totaling \$120,289 as follows:

Unrestricted	\$ 100,819
Temporarily Restricted	19,470
Total Cash	<u>\$ 120,289</u>

NORTHEAST LOUISIANA SICKLE CELL ANEMIA TECHNICAL
 RESOURCE FOUNDATION, INCORPORATED
 Monroe, Louisiana
 Notes to the Financial Statements (Continued)

The cash equivalents of the Foundation consisted of the following amounts invested in two (2) certificates of deposit at December 31, 2001:

Unrestricted	\$ 23,832
Temporarily Restricted	-
Total Cash Equivalents	<u>\$ 23,832</u>

These certificates bear interest rates of 7.75% and 4.25%, respectively with automatic renewal terms and maturity every 182 days and 6 months, respectively.

Total Columns

Total columns are presented to facilitate financial analysis. Data in these columns do not present financial position, results of operations and changes in net assets in conformity with generally accepted accounting principles. Neither is such data comparable to a consolidation.

NOTE 2. PHYSICAL PROPERTIES

Physical Properties consisted of the following at December 31, 2001:

	Balance 12/31/00	Additions	Deletions	Balance 12/31/01
Furniture and Equipment	\$ 23,776	\$ 2,385	\$ -	\$ 26,161
Building	201,730	-	-	201,730
Land	1,000	-	-	1,000
Less Accumulated Depreciation	(36,172)	(8,676)	-	(44,848)
	<u>\$ 190,334</u>	<u>\$ (6,291)</u>	<u>\$ -</u>	<u>\$ 184,043</u>

NOTE 3. PENSION PLAN

All employees of the Foundation are members of the Social Security System. In addition to the employees' contribution of 7.65 percent, the agency contributes an equal amount to the Social Security System. The Foundation does not guarantee the benefits granted by the Social Security System.

NOTE 4. DEFERRED REVENUE

Deferred revenue consists of the following:

Unrestricted	\$ 7,358
Total	<u>\$ 7,358</u>

NOTE 5. FAIR VALUE OF FINANCIAL INSTRUMENTS

The estimated fair values of the Agency's financial instruments, none of which are held for trading purposes, are as follows:

	<u>Carrying Amount</u>	<u>Fair Value</u>
Financial Assets:		
Cash and Cash Equivalents	\$ 120,289	\$ 120,289
Total	<u>\$ 120,289</u>	<u>\$ 120,289</u>

NOTE 6. FUNCTIONAL ALLOCATION OF EXPENSES

The costs of providing the various programs and activities have been summarized on a functional basis in the statement of activities. Accordingly, certain costs have been allocated among the programs and supporting services benefited.

NOTE 7. DONATED SERVICES

The value of donated services is not reflected in the accompanying financial statements since there is no objective basis available by which to measure the value of such services. However, for the purposes of this reports the amounts are immaterial.

NOTE 8. COMPENSATED ABSENCES

Compensated absences are absences for which employees will be paid, such as vacation, sick leave, and sabbatical leave. The Foundation has no policy for compensated

absences. Therefore, those costs are not reflected in this report. However, for the purpose of this report the amounts are considered immaterial.

NOTE 9. FUND DESCRIPTION

For internal accounting purposes, the Organization maintains the following separate funds:

GENERAL FUND

All assets over which the Board of Directors has discretionary control have been included in the General Fund.

UNITED WAY FUND

The United Way Fund is used to account for a grant from United Way of Northeast Louisiana.

STATE GRANT FUND

The State Grant Fund is used to account for a state grant from the Louisiana Department of Health and Hospitals.



ROSIE D. HARPER

Certified Public Accountant

141 DeSiard Street, Suite 325
Monroe, Louisiana 71201

Office 318-387-8008
FAX 318-387-0806

**REPORT ON COMPLIANCE AND ON INTERNAL CONTROL OVER
FINANCIAL REPORTING BASED ON AN AUDIT OF FINANCIAL
STATEMENTS PERFORMED IN ACCORDANCE WITH *GOVERNMENT
AUDITING STANDARDS***

To: The Board of Director's of Northeast
Louisiana Sickle Cell Anemia Resource
Foundation, Incorporated
Monroe, Louisiana

I have audited the financial statements of Northeast Louisiana Sickle Cell Anemia Resource Foundation, Incorporated as of and for the year ended December 31, 2001, and have issued my report thereon dated February 28, 2002. I conducted my audit in accordance with generally accepted auditing standards and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States.

Compliance

As part of obtaining reasonable assurance about whether Northeast Louisiana Sickle Cell Anemia Resource Foundation, Incorporated financial statements are free of material misstatement, I performed tests of its compliance with certain provisions of laws, regulations, contracts and grants, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of my audit and, accordingly, I do not express such an opinion. The results of my tests disclosed no instances of noncompliance that are required to be reported under *Government Auditing Standards*.

Internal Control Over Financial Reporting

In planning and performing my audit, I considered Northeast Louisiana Sickle Cell Anemia Resource Foundation, Incorporated internal control over financial reporting in order to determine my auditing procedures for the purpose of expressing my opinion on the financial statements and not to provide assurance on the internal control over financial reporting. My consideration of the internal control over financial reporting would not necessarily disclose all matters in the internal control over financial reporting that might be material weaknesses. A material weakness is a condition in which the design or operation of one or more of the internal control components does not reduce to a relatively low level the risk that misstatements in amounts that would be material in relation to the financial statements being audited may occur and not be detected within a timely period by employees in the normal course of performing their assigned functions.

**REPORT ON COMPLIANCE AND ON INTERNAL CONTROL OVER
FINANCIAL REPORTING BASED ON AN AUDIT OF FINANCIAL
STATEMENTS PERFORMED IN ACCORDANCE WITH *GOVERNMENT
AUDITING STANDARDS***

I noted no matters involving the internal control over financial reporting and its operation that I consider to be material weaknesses.

This report is intended solely for the information and use of the audit committee, management, Board of Directors, and granting agencies and is not intended to be and should not be used by anyone other than these specified parties.



Rosie D. Harper
Certified Public Accountant

February 28, 2002
Monroe, Louisiana

SUPPLEMENTAL INFORMATION

NORTHEAST LOUISIANA SICKLE CELL ANEMIA
 TECHNICAL RESOURCE FOUNDATION, INCORPORATED
 Schedule of Financial Position
 December 31, 2001

	<u>Temporarily Restricted</u>			<u>Total All Funds</u>
	<u>General Fund</u>	<u>United Way</u>	<u>Genetic Disease Fund</u>	
Assets				
Current Assets:				
Cash and Cash Equivalents	\$ 100,819	\$ 4,778	\$ 14,692	\$ 120,289
Accounts Receivable	-	-	-	-
Due From Other Funds	12,112	-	-	12,112
Total Current Assets	<u>112,931</u>	<u>4,778</u>	<u>14,692</u>	<u>132,401</u>
Physical Properties				
Furniture and Equipment	25,516	-	645	26,161
Building	201,730	-	-	201,730
Accumulated Depreciation	(44,719)	-	(129)	(44,848)
Land	1,000	-	-	1,000
Total Physical Properties	<u>183,527</u>	<u>-</u>	<u>516</u>	<u>184,043</u>
Total Assets	<u><u>296,458</u></u>	<u><u>4,778</u></u>	<u><u>15,208</u></u>	<u><u>316,444</u></u>
Liabilities and Net Assets				
Current Liabilities:				
Accrued Liabilities	3,185	-	-	3,185
Due to Other Funds	-	4,778	7,334	12,112
Deferred Revenue	-	-	7,358	7,358
Total Current Liabilities	<u>3,185</u>	<u>4,778</u>	<u>14,692</u>	<u>22,655</u>
Net Assets:				
Unrestricted, including \$183,527 invested in Physical Properties, Note 3	<u>293,273</u>	<u>-</u>	<u>516</u>	<u>293,789</u>
Total Net Assets	<u>293,273</u>	<u>-</u>	<u>516</u>	<u>293,789</u>
Total Liabilities and Net Assets	<u><u>\$ 296,458</u></u>	<u><u>\$ 4,778</u></u>	<u><u>\$ 15,208</u></u>	<u><u>\$ 316,444</u></u>

See accompanying notes to financial statements.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA
 TECHNICAL RESOURCE FOUNDATION, INCORPORATED
 Schedule of Activities
 For the Year Ended December 31, 2001

	<u>Unrestricted</u>	<u>Temporarily Restricted</u>		<u>Total All Funds</u>
	<u>General Fund</u>	<u>United Way</u>	<u>Genetic Disease Fund</u>	
Unrestricted Public Support and Revenues				
Contributions	\$ 12,590	\$ -	\$ -	\$ 12,590
Donations	20,183	-	-	20,183
Investment Income	1,019	-	-	1,019
Total Unrestricted Public Support and Revenues	<u>33,792</u>	<u>-</u>	<u>-</u>	<u>33,792</u>
Reclassified Net Assets				
Restrictions satisfied by payments	73,993	-	-	73,993
Total Reclassification Net Assets	<u>73,993</u>	<u>-</u>	<u>-</u>	<u>73,993</u>
Total Unrestricted Public Support, Revenues, and Reclassified Net Assets	<u>107,785</u>	<u>-</u>	<u>-</u>	<u>107,785</u>
Expenses				
Program Expenses	26,514	-	-	26,514
General & Administrative Expenses	84,268	-	-	84,268
Total Expenses	<u>110,782</u>	<u>-</u>	<u>-</u>	<u>110,782</u>
Change in unrestricted Net Assets	<u>(2,997)</u>	<u>-</u>	<u>-</u>	<u>(2,997)</u>
Temporarily Restricted Public Support and Revenues				
Grants	-	28,778	45,731	74,509
Net Assets Released from Restrictions:				
Restrictions satisfied by payments	-	(28,778)	(45,215)	(73,993)
Total Temporarily Restricted Public Support, Revenues, and Net Assets Released from Restrictions	<u>-</u>	<u>-</u>	<u>516</u>	<u>516</u>
Change in Temporarily Restricted Net Assets	<u>-</u>	<u>-</u>	<u>516</u>	<u>516</u>
Total change in net assets	<u>(2,997)</u>	<u>-</u>	<u>516</u>	<u>(2,481)</u>
Net assets as of beginning of year	296,270	-	-	296,270
Net assets as of end of year	<u>\$ 293,273</u>	<u>\$ -</u>	<u>\$ 516</u>	<u>\$ 293,789</u>

See accompanying notes to financial statements.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED
Schedule of Cash Flows
For the Year Ended December 31, 2001

	<u>Unrestricted</u>	<u>Temporarily Restricted</u>		
	<u>General</u>	<u>United</u>	<u>Genetic</u>	
	<u>Fund</u>	<u>Way</u>	<u>Disease</u>	<u>Total</u>
			<u>Fund</u>	<u>All Funds</u>
Operating Activities				
Change in Net Assets	\$ (2,997)	\$ -	\$ 516	\$ (2,481)
Adjustments to reconcile change in net assets to net cash provided by operating activities:				
Provision for Depreciation	8,547	-	129	8,676
Decrease (Increase) in Due from Other Funds	(1,761)	-	-	(1,761)
Decrease (Increase) in Grants Receivable/Other Receivables	1,786	-	-	1,786
Increase (Decrease) in Accrued Liabilities	3,185	-	-	3,185
Increase (Decrease) in Due to Other Funds	-	1,521	240	1,761
Increase in Donated Assets	-	-	-	-
Increase (Decrease) in Deferred Income	-	-	4,894	4,894
Total Adjustments	<u>11,757</u>	<u>1,521</u>	<u>5,263</u>	<u>18,541</u>
Net Cash Provided by Operating Activities	<u>8,760</u>	<u>1,521</u>	<u>5,779</u>	<u>16,060</u>
Investing Activities				
Acquisitions of Physical Properties	<u>(1,740)</u>	<u>-</u>	<u>(645)</u>	<u>(2,385)</u>
Net Cash Used by Investing Activities	<u>(1,740)</u>	<u>-</u>	<u>(645)</u>	<u>(2,385)</u>
Increase (Decrease) in Cash and Cash Equivalents	7,020	1,521	5,134	13,675
Cash and Cash Equivalents at the Beginning of Year	<u>93,799</u>	<u>3,257</u>	<u>9,558</u>	<u>106,614</u>
Cash and Cash Equivalents at the End of Year	<u>\$ 100,819</u>	<u>\$ 4,778</u>	<u>\$ 14,692</u>	<u>\$ 120,289</u>
Supplemental Information:				
Cash Equivalents				
Certificates of Deposits	<u>\$ 23,832</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 23,832</u>

See accompanying notes to financial statements.

NORTHEAST LOUISIANA SICKLE CELL ANEMIA
TECHNICAL RESOURCE FOUNDATION, INCORPORATED
Schedule of Functional Expenses
For the Year Ended December 31, 2001

	<u>Temporarily Restricted Net Assets Released From Restrictions</u>			<u>Total All Funds</u>
	<u>General Fund</u>	<u>United Way Fund</u>	<u>Genetic Disease Fund</u>	
Program Expenses				
Personnel Costs				
Salaries and Wages	\$ -	\$ 20,760	\$ -	\$ 20,760
Payroll Taxes and other Fringe Benefits	-	1,588	-	1,588
Total Personnel Costs	-	22,348	-	22,348
Other Expenses				
Contributions	500	-	-	500
Specific Assistance to Individuals	217	-	2,508	2,725
Travel	-	941	-	941
Total Other Expenses	717	941	2,508	4,166
Total Program Expenses	717	23,289	2,508	26,514
General & Administrative Expenses				
Personnel Costs				
Salaries and Wages	3,229	-	30,403	33,632
Payroll Taxes and other Fringe Benefits	247	-	2,326	2,573
Total Personnel Costs	3,476	-	32,729	36,205
Other Expenses				
Bank Charges	174	117	-	291
Bldg & Lawn Service	1,230	-	30	1,260
Car Allowance	700	-	-	700
Conferences, Conventions, & Meetings	-	-	271	271
Depreciation Expense	8,547	-	129	8,676
Fundraiser	462	-	-	462
Insurance	1,152	-	1,809	2,961
Internet	262	-	-	262
Miscellaneous	5,109	-	155	5,264
Occupancy	401	-	-	401
Postage and Delivery	259	-	298	557
Printing and Publication	151	270	42	463
Professional/Contractual	7,690	1,500	2,000	11,190
Repairs	88	106	608	802
Supplies	3,044	-	956	4,000
Telephone	561	2,570	988	4,119
Travel	106	-	1,079	1,185
Utilities	2,660	926	1,613	5,199
Total Other Expenses	32,596	5,489	9,978	48,063
Total General & Administrative Expenses	36,072	5,489	42,707	84,268
Total Functional Expenses	\$ 36,789	\$ 28,778	\$ 45,215	\$ 110,782

See accompanying notes to financial statements.